2026 Workshop Programme

VAE have long been used in integrative oncology with documented immunomodulatory, cytotoxic and quality-of-life benefits. Meanwhile, ICIs have transformed oncologic therapy by re-activating antitumour immunity. However, primary and acquired resistance to ICIs remains a major clinical limitation. Combined findings from in vitro work and real-world data provide a compelling rationale that VAE may serve as adjuvants to ICI therapy, prolonging survival and reducing side-effects. In this workshop, some of these recent publications will be highlighted and supplemented with patient cases.